CO4600638A1 - Virosomas cationicos como sistema de transferencia para material genetico - Google Patents

Virosomas cationicos como sistema de transferencia para material genetico

Info

Publication number
CO4600638A1
CO4600638A1 CO97024481A CO97024481A CO4600638A1 CO 4600638 A1 CO4600638 A1 CO 4600638A1 CO 97024481 A CO97024481 A CO 97024481A CO 97024481 A CO97024481 A CO 97024481A CO 4600638 A1 CO4600638 A1 CO 4600638A1
Authority
CO
Colombia
Prior art keywords
fusion peptide
lipid bilayer
viral fusion
cationic
membrane
Prior art date
Application number
CO97024481A
Other languages
English (en)
Spanish (es)
Inventor
Peter Klein
Reinhard Gluck
Ernst Rudolf Walti
Original Assignee
Nika Health Products Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nika Health Products Ltd filed Critical Nika Health Products Ltd
Publication of CO4600638A1 publication Critical patent/CO4600638A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CO97024481A 1996-05-08 1997-05-07 Virosomas cationicos como sistema de transferencia para material genetico CO4600638A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96107282 1996-05-08

Publications (1)

Publication Number Publication Date
CO4600638A1 true CO4600638A1 (es) 1998-05-08

Family

ID=8222763

Family Applications (1)

Application Number Title Priority Date Filing Date
CO97024481A CO4600638A1 (es) 1996-05-08 1997-05-07 Virosomas cationicos como sistema de transferencia para material genetico

Country Status (28)

Country Link
US (1) US6210708B1 (enExample)
EP (1) EP0902682A2 (enExample)
JP (1) JP2000509404A (enExample)
KR (1) KR100536983B1 (enExample)
CN (1) CN1271992C (enExample)
AR (1) AR007054A1 (enExample)
AU (1) AU710170B2 (enExample)
BG (1) BG102880A (enExample)
BR (1) BR9709224A (enExample)
CA (1) CA2253561A1 (enExample)
CO (1) CO4600638A1 (enExample)
CZ (1) CZ299809B6 (enExample)
EA (1) EA003130B1 (enExample)
GT (1) GT199700058A (enExample)
HR (1) HRP970234B1 (enExample)
HU (1) HUP9901790A3 (enExample)
ID (1) ID17934A (enExample)
NO (1) NO327726B1 (enExample)
NZ (1) NZ332666A (enExample)
OA (1) OA10916A (enExample)
PA (1) PA8429201A1 (enExample)
PE (1) PE65198A1 (enExample)
PL (1) PL199201B1 (enExample)
SK (1) SK152698A3 (enExample)
SV (1) SV1997000032A (enExample)
TN (1) TNSN97080A1 (enExample)
WO (1) WO1997041834A1 (enExample)
ZA (1) ZA973885B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030113347A1 (en) * 1991-05-08 2003-06-19 Schweiz. Serum- & Impfinstitut Bern Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
AU9224398A (en) * 1997-09-08 1999-03-29 Promega Corporation Method of (in vivo) transformation utilizing lipid vehicles
SE513149C2 (sv) * 1997-12-05 2000-07-17 Katarina Edwards Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna
GB9813100D0 (en) * 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
CA2388053A1 (en) * 1999-10-08 2001-04-19 Nika Health Products Limited Cationic dosper virosomes
JP4112860B2 (ja) * 1999-12-17 2008-07-02 ショット アクチエンゲゼルシャフト 乗員の拘束システムの誘導作動式点火カプセルおよび点火カプセル用のテスト回路
EP1252897A4 (en) * 2000-01-21 2003-07-30 Hisamitsu Pharmaceutical Co MEDICINES FOR GENE THERAPY
JP2004536607A (ja) * 2001-07-23 2004-12-09 オニックス ファーマシューティカルズ，インコーポレイティド 標的化されたヒト癌細胞において選択的に複製するウイルス変異体
KR100411234B1 (ko) * 2001-08-14 2003-12-18 한국과학기술원 올리고뉴클레오티드 혼성화 미셀 및 그의 제조방법
WO2003038103A1 (en) * 2001-10-29 2003-05-08 Atso Raasmaja Method for gene transfection using synergistic combinations of cationic lipids and cationic polymers
US20040028687A1 (en) * 2002-01-15 2004-02-12 Waelti Ernst Rudolf Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues
US20040176283A1 (en) * 2002-04-01 2004-09-09 Robinson John A. Methods and compositions for the design of synthetic vaccines
EA008497B1 (ru) * 2002-11-21 2007-06-29 Певион Биотех Лтд. Высокоэффективные способные к слиянию везикулы, способ их получения и фармацевтическая композиция, их содержащая
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US20090208478A1 (en) * 2003-10-24 2009-08-20 Gencia Corporation Transducible polypeptides for modifying metabolism
AU2004297533B2 (en) 2003-10-24 2010-04-29 Gencia Corporation Methods and compositions for delivering polynucleotides
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
DE102004057303A1 (de) * 2004-11-26 2006-06-01 Merck Patent Gmbh Stabile Kristallmodifikationen von DOTAP Chlorid
US20070172520A1 (en) * 2005-11-18 2007-07-26 University Of South Florida Immunotargeting of Nonionic Surfactant Vesicles
WO2009016433A2 (en) * 2006-09-15 2009-02-05 Ottawa Health Research Institute Oncolytic rhabdovirus
KR101242113B1 (ko) * 2010-10-22 2013-03-19 고마바이오텍(주) 유전자 전달용 양이온성 센다이 ｆ／ｈｎ 바이로좀 복합체
WO2013032643A2 (en) * 2011-08-31 2013-03-07 Dicerna Pharmaceuticals, Inc. Lipids capable of conformational change and their use in formulations to deliver therapeutic agents to cells
WO2013050048A2 (en) * 2011-10-07 2013-04-11 Skau Aps Identification and attenuation of the immunosuppressive domains in fusion proteins of enveloped rna viruses
MX383392B (es) 2016-09-27 2025-03-13 Camurus Ab Mezclas y formulaciones que comprenden una sal de alquil amonio de ácido etilendiaminotetraacético (edta).
CN109055432B (zh) * 2018-08-16 2020-10-13 南京科佰生物科技有限公司 慢病毒感染试剂及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
PL296382A1 (en) * 1991-02-02 1993-11-02 Nika Health Products Ltd Li Li Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system
CA2086831C (en) * 1991-05-08 1999-03-16 Reinhard Gluck Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
AU3614493A (en) 1992-02-04 1993-09-01 Chiron Corporation Non-toxic lipid vaccine formulations
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
WO1995002698A1 (en) * 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
ATE223701T1 (de) * 1994-05-31 2002-09-15 Inex Pharmaceutical Corp Intrazelluläre verabreichung therapeutischer sustanzenmittels virosomen
FR2726764B1 (fr) 1994-11-14 1997-01-31 Pasteur Merieux Serums Vacc Adjuvant pour composition vaccinale

Also Published As

Publication number Publication date
AU710170B2 (en) 1999-09-16
GT199700058A (es) 1998-10-29
PE65198A1 (es) 1998-10-16
NO985137D0 (no) 1998-11-04
NZ332666A (en) 2000-05-26
NO327726B1 (no) 2009-09-14
EA199800992A1 (ru) 1999-06-24
EP0902682A2 (en) 1999-03-24
AU2776697A (en) 1997-11-26
KR20000010780A (ko) 2000-02-25
CN1271992C (zh) 2006-08-30
CZ299809B6 (cs) 2008-12-03
BG102880A (en) 1999-05-31
SV1997000032A (es) 1998-03-27
EA003130B1 (ru) 2003-02-27
ID17934A (id) 1998-02-12
PL329853A1 (en) 1999-04-12
HUP9901790A3 (en) 2010-11-29
JP2000509404A (ja) 2000-07-25
HRP970234B1 (en) 2002-04-30
OA10916A (en) 2003-02-21
HRP970234A2 (en) 1998-06-30
SK152698A3 (en) 1999-05-07
HUP9901790A2 (hu) 1999-08-30
BR9709224A (pt) 1999-08-10
ZA973885B (en) 1998-11-06
CA2253561A1 (en) 1997-11-13
CN1225007A (zh) 1999-08-04
NO985137L (no) 1999-01-04
KR100536983B1 (ko) 2006-06-29
US6210708B1 (en) 2001-04-03
PL199201B1 (pl) 2008-08-29
PA8429201A1 (es) 2000-05-24
AR007054A1 (es) 1999-10-13
CZ361498A3 (cs) 1999-03-17
WO1997041834A1 (en) 1997-11-13
TNSN97080A1 (fr) 2005-03-15

Similar Documents

Publication Publication Date Title
van Meer et al. The tight junction does not allow lipid molecules to diffuse from one epithelial cell to the next
Matsuzaki et al. Pore formation and translocation of melittin
Metsikkö et al. Reconstitution of the fusogenic activity of vesicular stomatitis virus.
van Meer et al. The function of tight junctions in maintaining differences in lipid composition between the apical and the basolateral cell surface domains of MDCK cells.
Durrer et al. H+-induced membrane insertion of influenza virus hemagglutinin involves the HA2 amino-terminal fusion peptide but not the coiled coil region
Greber et al. Mechanisms of virus uncoating
JP2000509404A (ja) 遺伝物質の導入システムとしてのカチオン性ヴィロソーム
FI924418A0 (fi) Blaosor av syntetisk membran som innehaoller funktionellt aktiva fusionspeptider som laekemedel befriande system.
Dowdall et al. Recent studies on the comparative biochemistry of the cholinergic neuron
Heine et al. Fusion of vesicular stomatitis virus with the cytoplasmic membrane of L cells
WO2024093036A1 (en) A method to increase the loading of specific nucleic acid molecules in engineered cell exosomes and its application
Kosower et al. Membrane mobility agents. IV. The mechanism of particle-cell and cell-cell fusion
Pak et al. Detection of influenza hemagglutinin interaction with biological membranes by photosensitized activation of [125I] iodonaphthylazide.
US6875448B1 (en) Method of intracellular sustained-release of drug and preparations
Semin et al. Calorimetric studies of cytochrome oxidase-phospholipid interactions
Benson et al. Biochemical and cytochemical evidence indicates that coated vesicles in chick embryo myotubes contain newly synthesized acetylcholinesterase.
Lucy Fusogenic mechanisms
EP1332220B1 (en) Oligonucleotide - facilitated coalescence
Franklin et al. Structure and assembly of lipid-containing viruses, with special reference to bacteriophage PM2 as one type of model system
Johannes et al. Uptake of the restriction endonuclease Alu I by Chinese hamster ovary cells measured by frequencies of induced chromosomal aberrations: effect of hypertonic concentrations of glycerol and sorbitol
Lucy et al. Osmotic forces and the fusion of biomembranes
Oku et al. pH-dependent fusion of lipid vesicles induced by proton-sensitive polymer
Zeichner Isolation and characterization of phagosomes containing Chlamydia psittaci from L cells
Pozzi et al. Use of octadecylrhodamine fluorescence dequenching to study vesicular stomatitis virus fusion with human aged red blood cells
Imazu et al. A novel nonviral vector based on vesicular stomatitis virus